Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H van Rennes

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Anti-Cancer Drugs|April 1, 1995
Schedule-dependent enhancement of antitumor activity of ethyldeshydroxy-sparsomycin in combination with classical antineoplastic agentsH P Hofs, D J Wagener, V de Valk-Bakker, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclonesH P Hofs, D J Wagener, V de Valk-Bakker, et al.
Anticancer Research|January 1, 1992
Potentiation of cisplatin antitumour activity by Ethyldeshydroxy-Sparsomycin in L1210 leukemiaH P Hofs, D J Wagener, V De Valk-Bakker, et al.
Cancer Letters|July 1, 1986
In vivo potentiation of cis-diamminedichloroplatinum (II) antitumor activity by pretreatment with sparsomycinZ Zylicz, D J Wagener, H van Rennes, et al.
Investigational New Drugs|January 1, 1995
Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatinH P Hofs, D J Wagener, V De Valk-Bakker, et al.
Journal of the National Cancer Institute|April 1, 1987
In vitro modulation of cisplatin cytotoxicity by sparsomycin inhibition of protein synthesisZ Zylicz, D J Wagener, H van Rennes, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
Pharmacokinetics and toxicology of sparsomycin in beagle dogsZ Zylicz, D J Wagener, P Fernandez del Moral, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Anti-Cancer Drugs|April 1, 1995
Schedule-dependent enhancement of antitumor activity of ethyldeshydroxy-sparsomycin in combination with classical antineoplastic agentsH P Hofs, D J Wagener, V de Valk-Bakker, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclonesH P Hofs, D J Wagener, V de Valk-Bakker, et al.
Anticancer Research|January 1, 1992
Potentiation of cisplatin antitumour activity by Ethyldeshydroxy-Sparsomycin in L1210 leukemiaH P Hofs, D J Wagener, V De Valk-Bakker, et al.
Cancer Letters|July 1, 1986
In vivo potentiation of cis-diamminedichloroplatinum (II) antitumor activity by pretreatment with sparsomycinZ Zylicz, D J Wagener, H van Rennes, et al.
Investigational New Drugs|January 1, 1995
Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatinH P Hofs, D J Wagener, V De Valk-Bakker, et al.
Journal of the National Cancer Institute|April 1, 1987
In vitro modulation of cisplatin cytotoxicity by sparsomycin inhibition of protein synthesisZ Zylicz, D J Wagener, H van Rennes, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1987
Pharmacokinetics and toxicology of sparsomycin in beagle dogsZ Zylicz, D J Wagener, P Fernandez del Moral, et al.
Pageof 3